留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

循环microRNA作为肝细胞癌标志物的研究现状

谢惠君 RashedNasot 宁勇 高川

谢惠君, Rashed Nasot, 宁勇, 等. 循环miRNA作为肝细胞癌标志物的研究现状[J]. 临床肝胆病杂志, 2021, 37(2): 448-451. DOI: 10.3969/j.issn.1001-5256.2021.02.042
引用本文: 谢惠君, Rashed Nasot, 宁勇, 等. 循环miRNA作为肝细胞癌标志物的研究现状[J]. 临床肝胆病杂志, 2021, 37(2): 448-451. DOI: 10.3969/j.issn.1001-5256.2021.02.042
XIE HJ, RASHED N, NING Y, et al. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma [J]. J Clin Hepatol, 2021, 37(2): 448-451. DOI: 10.3969/j.issn.1001-5256.2021.02.042
Citation: XIE HJ, RASHED N, NING Y, et al. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma [J]. J Clin Hepatol, 2021, 37(2): 448-451. DOI: 10.3969/j.issn.1001-5256.2021.02.042

循环microRNA作为肝细胞癌标志物的研究现状

DOI: 10.3969/j.issn.1001-5256.2021.02.042
基金项目: 

湖北省“楚天学者计划”资助项目 鄂教师函〔2016〕4号

详细信息
    作者简介:

    谢惠君(1996—),女,主要从事临床检验诊断学方面的研究

    通讯作者:

    高川,cgao@hbtcm.edu.cn

  • 作者贡献声明:高川、宁勇负责课题设计;谢惠君、Rashed Nasot、高川撰写论文初稿;Rashed Nasot、宁勇参与收集数据和修改论文;宁勇指导撰写文章;高川、宁勇最后定稿。
  • 中图分类号: R735.7

Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma

  • 摘要: 肝细胞癌(HCC)是最常见的原发性肝癌,其高死亡率与当前对HCC的诊断和监测手段不理想密切相关。microRNA(miRNA)在HCC的发生和进展过程中发挥重要作用,其异常表达是HCC病理中的常见现象,且miRNA能被细胞释放到循环血中稳定存在。通过讨论miRNA在HCC中作用的研究进展,提出循环miRNA有望成为HCC早期诊断、监测治疗和评估预后的潜在标志物,并分析了现阶段该潜在标志物在临床验证中所面临的问题。
  • [1] SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590
    [2] LI X, GAO ZF, YAN J. Value of tumor markers in the diagnosis of early-stage primary liver cancer and related research advances[J/CD]. Electronic J Liver Tumor, 2014, 1(3): 41-45.(in Chinese)

    李汛, 高增法, 严俊. 肿瘤标志物对早期原发性肝癌的诊断价值与研究进展[J/CD]. 肝癌电子杂志, 2014, 1(3): 41-45.
    [3] MCGLYNN KA, PETRICK JL, EL-SERAG HB. Epidemiology of hepatocellular carcinoma[J]. Hepatology, 2020.[Epub ahead of print]
    [4] HA M, KIM VN. Regulation of microRNA biogenesis[J]. Nat Rev Mol Cell Biol, 2014, 15(8): 509-524. DOI: 10.1038/nrm3838
    [5] KOZOMARA A, BIRGAOANU M, GRIFFITHS-JONES S. miRBase: From microRNA sequences to function[J]. Nucleic Acids Res, 2019, 47(D1): d155-d162. DOI: 10.1093/nar/gky1141
    [6] VICKERS KC, PALMISANO BT, SHOUCRI BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins[J]. Nat Cell Biol, 2011, 13(4): 423-433. DOI: 10.1038/ncb2210
    [7] GEEKIYANAGE H, RAYATPISHEH S, WOHLSCHLEGEL JA, et al. Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides[J]. Proc Natl Acad Sci U S A, 2020, 117(39): 24213-24223. DOI: 10.1073/pnas.2008323117
    [8] HAND NJ, MASTER ZR, LE LAY J, et al. Hepatic function is preserved in the absence of mature microRNAs[J]. Hepatology, 2009, 49(2): 618-626. DOI: 10.1002/hep.22656
    [9] SEKINE S, OGAWA R, ITO R, et al. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis[J]. Gastroenterology, 2009, 136(7): 2304-2315. DOI: 10.1053/j.gastro.2009.02.067
    [10] JIANG M, GONG X, XIAO XQ, et al. Expression of serum miRNA-122-3p in patients with CHB treated with PEG-interferon-alpha 2b[J]. Int J Virol, 2019, 26(5): 293-298.(in Chinese) DOI: 10.3760/cma.j.issn.1673-4092.2019.05.002

    蒋敏, 龚兴, 肖新强, 等. 血清miRNA-122-3p在聚乙二醇干扰素-α2b治疗CHB患者中表达的研究[J]. 国际病毒学杂志, 2019, 26(5): 293-298. DOI: 10.3760/cma.j.issn.1673-4092.2019.05.002
    [11] BANDIERA S, PFEFFER S, BAUMERT TF, et al. miR-122-a key factor and therapeutic target in liver disease[J]. J Hepatol, 2015, 62(2): 448-457. DOI: 10.1016/j.jhep.2014.10.004
    [12] XUE X, ZHAO NY, YU HT, et al. Discovery of novel inhibitors disrupting HIF-1α/von Hippel-Lindau interaction through shape-based screening and cascade docking[J]. PeerJ, 2016, 4: e2757. DOI: 10.7717/peerj.2757
    [13] LI M, TANG Y, WU L, et al. The hepatocyte-specific HNF4α/miR-122 pathway contributes to iron overload-mediated hepatic inflammation[J]. Blood, 2017, 130(8): 1041-1051. DOI: 10.1182/blood-2016-12-755967
    [14] SHAN LQ, FANG Z, LIU H, et al.Mechanism of miR-92a in promoting proliferation and migration of hepatoma cells by down-regulating expression of RAB3B[J]. J Clin Exp Med, 2019, 18(12): 1266-1270.(in Chinese) DOI: 10.3969/j.issn.1671-4695.2019.12.010

    单留群, 方征, 刘洪, 等. miR-92a通过下调RAB3B表达促进肝癌细胞增殖、迁移的机制分析[J]. 临床和实验医学杂志, 2019, 18(12): 1266-1270. DOI: 10.3969/j.issn.1671-4695.2019.12.010
    [15] MURAKAMI Y, YASUDA T, SAIGO K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues[J]. Oncogene, 2006, 25(17): 2537-2545. DOI: 10.1038/sj.onc.1209283
    [16] JIANG J, GUSEV Y, ADERCA I, et al. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival[J]. Clin Cancer Res, 2008, 14(2): 419-427. DOI: 10.1158/1078-0432.CCR-07-0523
    [17] PARK JK, KOGURE T, NUOVO GJ, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival[J]. Cancer Res, 2011, 71(24): 7608-7616. DOI: 10.1158/0008-5472.CAN-11-1144
    [18] LI H, XIANG Z, LIU Y, et al. MicroRNA-133b inhibits proliferation, cellular migration, and invasion via targeting LASP1 in hepatocarcinoma cells[J]. Oncol Res, 2017, 25(8): 1269-1282. DOI: 10.3727/096504017X14850151453092
    [19] XIAN Y, WANG L, YAO B, et al. MicroRNA-769-5p contributes to the proliferation, migration and invasion of hepatocellular carcinoma cells by attenuating RYBP[J]. Biomed Pharmacother, 2019, 118: 109343. DOI: 10.1016/j.biopha.2019.109343
    [20] WU JY, LAI ZD, TIAN YF, et al. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. J Clin Hepatol, 2020, 36(8): 1768-1772. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.08.018

    吴俊艺, 赖智德, 田毅峰, 等. 血清外泌体来源的microRNA-221-3p在肝细胞癌中的表达及意义[J]. 临床肝胆病杂志, 2020, 36(8): 1768-1772. DOI: 10.3969/j.issn.1001-5256.2020.08.018
    [21] WONG CC, AU SL, TSE AP, et al. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis[J]. PLoS One, 2014, 9(12): e115036. DOI: 10.1371/journal.pone.0115036
    [22] FORNARI F, GRAMANTIERI L, GIOVANNINI C, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells[J]. Cancer Res, 2009, 69(14): 5761-5767. DOI: 10.1158/0008-5472.CAN-08-4797
    [23] WANG SC, LIN XL, LI J, et al. MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA[J]. PLoS One, 2014, 9(7): e101330. DOI: 10.1371/journal.pone.0101330
    [24] GUO W, QIU Z, WANG Z, et al. MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer[J]. Hepatology, 2015, 62(4): 1132-1144. DOI: 10.1002/hep.27929
    [25] ZHANG LF, LOU JT, LU MH, et al. Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma[J]. EMBO J, 2015, 34(21): 2671-2685. DOI: 10.15252/embj.201591803
    [26] FORNARI F, MILAZZO M, CHIECO P, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells[J]. Cancer Res, 2010, 70(12): 5184-5193. DOI: 10.1158/0008-5472.CAN-10-0145
    [27] HOU J, LIN L, ZHOU W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma[J]. Cancer Cell, 2011, 19(2): 232-243. DOI: 10.1016/j.ccr.2011.01.001
    [28] LIU Z, LI W, PANG Y, et al. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma[J]. EBioMedicine, 2018, 38: 57-68. DOI: 10.1016/j.ebiom.2018.10.067
    [29] FORNARI F, GRAMANTIERI L, FERRACIN M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma[J]. Oncogene, 2008, 27(43): 5651-5661. DOI: 10.1038/onc.2008.178
    [30] PINEAU P, VOLINIA S, MCJUNKIN K, et al. miR-221 overexpression contributes to liver tumorigenesis[J]. Proc Natl Acad Sci U S A, 2010, 107(1): 264-269. DOI: 10.1073/pnas.0907904107
    [31] GRAMANTIERI L, FORNARI F, FERRACIN M, et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality[J]. Clin Cancer Res, 2009, 15(16): 5073-5081. DOI: 10.1158/1078-0432.CCR-09-0092
    [32] FORNARI F, POLLUTRI D, PATRIZI C, et al. In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of Caspase-3-mediated apoptosis[J]. Clin Cancer Res, 2017, 23(14): 3953-3965. DOI: 10.1158/1078-0432.CCR-16-1464
    [33] LI LM, HU ZB, ZHOU ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma[J]. Cancer Res, 2010, 70(23): 9798-9807. DOI: 10.1158/0008-5472.CAN-10-1001
    [34] ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36): 4781-4788. DOI: 10.1200/JCO.2011.38.2697
    [35] LIN XJ, CHONG Y, GUO ZW, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: A multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study[J]. Lancet Oncol, 2015, 16(7): 804-815. DOI: 10.1016/S1470-2045(15)00048-0
    [36] EL-ABD NE, FAWZY NA, EL-SHEIKH SM, et al. Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in egyptian patients with chronic hepatitis C virus infection[J]. Mol Diagn Ther, 2015, 19(4): 213-220. DOI: 10.1007/s40291-015-0148-1
    [37] NOMAIR AM, ISSA NM, MADKOUR MA, et al. The clinical significance of serum miRNA-224 expression in hepatocellular carcinoma[J]. Clin Exp Hepatol, 2020, 6(1): 20-27. DOI: 10.5114/ceh.2020.93052
    [38] de RIE D, ABUGESSAISA I, ALAM T, et al. An integrated expression atlas of miRNAs and their promoters in human and mouse[J]. Nat Biotechnol, 2017, 35(9): 872-878. DOI: 10.1038/nbt.3947
    [39] DA FONSECA B, DOMINGUES DS, PASCHOAL AR. mirtronDB: A mirtron knowledge base[J]. Bioinformatics, 2019, 35(19): 3873-3874. DOI: 10.1093/bioinformatics/btz153
    [40] LIU M, ROTH A, YU M, et al. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis[J]. Genes Dev, 2013, 27(23): 2543-2548. DOI: 10.1101/gad.224170.113
    [41] SHANG R, BAEK SC, KIM K, et al. Genomic clustering facilitates nuclear processing of suboptimal pri-miRNA loci[J]. Mol Cell, 2020, 78(2): 303-316. DOI: 10.1016/j.molcel.2020.02.009
    [42] CANTINI L, BERTOLI G, CAVA C, et al. Identification of microRNA clusters cooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer[J]. Nucleic Acids Res, 2019, 47(5): 2205-2215. DOI: 10.1093/nar/gkz016
    [43] WU J, DONG T, CHEN T, et al. Hepatic exosome-derived miR-130a-3p attenuates glucose intolerance via suppressing PHLPP2 gene in adipocyte[J]. Metabolism, 2020, 103: 154006. DOI: 10.1016/j.metabol.2019.154006
    [44] DING J, XU Z, ZHANG Y, et al. Exosome-mediated miR-222 transferring: An insight into NF-κB-mediated breast cancer metastasis[J]. Exp Cell Res, 2018, 369(1): 129-138. DOI: 10.1016/j.yexcr.2018.05.014
    [45] WEBER JA, BAXTER DH, ZHANG S, et al. The microRNA spectrum in 12 body fluids[J]. Clin Chem, 2010, 56(11): 1733-1741. DOI: 10.1373/clinchem.2010.147405
    [46] HEEGAARD NH, SCHETTER AJ, WELSH JA, et al. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer[J]. Int J Cancer, 2012, 130(6): 1378-1386. DOI: 10.1002/ijc.26153
    [47] HENEGHAN HM, MILLER N, LOWERY AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer[J]. Ann Surg, 2010, 251(3): 499-505. DOI: 10.1097/SLA.0b013e3181cc939f
    [48] KROH EM, PARKIN RK, MITCHELL PS, et al. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR)[J]. Methods, 2010, 50(4): 298-301. DOI: 10.1016/j.ymeth.2010.01.032
    [49] XU J, WU C, CHE X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis[J]. Mol Carcinog, 2011, 50(2): 136-142. DOI: 10.1002/mc.20712
    [50] PELTIER HJ, LATHAM GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues[J]. RNA, 2008, 14(5): 844-852. DOI: 10.1261/rna.939908
    [51] WANG R, ZHU X, XING Y, et al. Multitag-regulated cascade reaction: A generalizable ultrasensitive microRNA biosensing approach for cancer prognosis[J]. ACS Appl Mater Interfaces, 2019, 11(40): 36444-36448. DOI: 10.1021/acsami.9b14452
    [52] QIU X, HILDEBRANDT N. Rapid and multiplexed microRNA diagnostic assay using quantum dot-based förster resonance energy transfer[J]. ACS Nano, 2015, 9(8): 8449-8457. DOI: 10.1021/acsnano.5b03364
    [53] GIRAY BG, EMEKDAS G, TEZCAN S, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma[J]. Mol Biol Rep, 2014, 41(7): 4513-4519. DOI: 10.1007/s11033-014-3322-3
  • 加载中
计量
  • 文章访问数:  21
  • HTML全文浏览量:  4
  • PDF下载量:  11
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-11-06
  • 修回日期:  2020-12-16
  • 刊出日期:  2021-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回